Objective To systematically evaluate the clinical effect of remote ischaemic preconditioning (RIPC) in selective vascular surgery. Methods PubMed, The Cochrane Library, Web of Science, EMbase, CNKI, Wanfang Data, VIP and CBM were retrieved to gather relevant literatures. Relevant randomized controlled trials were screened according to inclusion and exclusion criteria. Meta-analysis was performed using RevMan 5.3 software. Results A total of 16 studies were included, involving 1 507 patients. There was no statistical difference between RIPC and non-RIPC in reducing perioperative mortality in elective vascular surgery. There were no statistical differences between the two groups in the incidence of myocardial infarction, kidney injury, postoperative stroke, postoperative length of hospital stay, the total duration of surgery or anesthesia, limb injury, arrhythmia, heart failure or pneumonia. Conclusion For patients undergoing elective vascular surgery, there may no statistical in perioperative mortality and other clinical endpoints between RIPC and non-RIPC patients.
ObjectiveTo investigate effectiveness and safety of transcatheter aortic valve replacement in the treatment of aortic regurgitation. Methods PubMed, EMbase, The Cochrane Library, Web of Science, CNKI, Wanfang Data and VIP were searched from inception to August 2021. According to the criteria of inclusion and exclusion, two reviewers independently screened the literature, extracted the data and evaluated the quality of the included studies. Then, Stata 16.0 software was used for meta-analysis. Subgroup meta-analysis of valve type used and study type was performed. ResultsTwenty-five studies (12 cohort studies and 13 single-arm studies) were included with 4 370 patients. Meta-analysis results showed that an incidence of device success was 87% (95%CI 0.81-0.92). The success rate of the new generation valve subgroup was 93% (95%CI 0.89-0.96), and the early generation valve subgroup was 66% (95%CI 0.56-0.75). In addition, the 30-day all-cause mortality was 7% (95%CI 0.05-0.10), the 30-day cardiac mortality was 4% (95%CI 0.01-0.07), the incidence of pacemaker implantation was 10% (95%CI 0.08-0.13), and the incidence of conversion to thoracotomy was 2% (95%CI 0.01-0.04). The incidence of moderate or higher paravalvular aortic regurgitation was 6% (95%CI 0.03-0.09). Conclusion Transcatheter aortic valve replacement for aortic regurgitation is safe and yields good results, but some limitations can not be overcome. Therefore, multicenter randomized controlled trials are needed to confirm our results.